Restore & Recover
Supports recovery and tissue resilience.
BPC-157 + TB-500Optional: NAD+
Peptide therapy
TB-500, Thymosin Beta-4 Fragment Research Peptide
A synthetic fragment of thymosin beta-4 studied in animal injury models for cell migration and tissue repair. Human RCT data is absent.
TB-500 is a synthetic fragment of thymosin beta-4, a naturally occurring protein involved in cell migration and tissue repair. It is widely discussed in recovery contexts, but the human evidence base is essentially zero. Animal data is suggestive. Human RCTs do not exist.
This page explains what TB-500 is, what the preclinical research shows, what FDA's current regulatory position looks like, and how Genesis Longevity frames its responsible use.
What it is
About this therapy
TB-500 is a synthetic fragment of thymosin beta-4, a 43-amino-acid protein involved in cell migration and tissue repair that occurs naturally in nearly all human and animal cells. TB-500 itself is the active fragment researchers have isolated for study.
It is described as a research compound because no pharmaceutical company has completed the large-scale, placebo-controlled human trials required for FDA drug approval. This is not because it is known to be ineffective. The economics of peptide development (low cost to synthesize, limited patent protection) do not justify the investment a New Drug Application requires.
TB-500 is available in the United States only through 503A compounding pharmacies with a valid provider prescription. That availability is subject to ongoing FDA regulatory action. The FDA Pharmacy Compounding Advisory Committee (PCAC) reviewed both BPC-157 and TB-500 at its July 2026 meeting for potential 503A list inclusion.
How it works
Mechanism of action
Mechanisms below derive from preclinical models, cell cultures and rodents primarily. Human mechanistic studies confirming these pathways at compounded injectable doses do not exist.
- Sequesters monomeric G-actin, enabling accelerated cell migration to injury sites.
- Promotes endothelial cell migration and angiogenesis.
- Mobilizes stem cells from bone marrow toward tissue injury.
- Reduces NF-κB-driven inflammation and may polarize macrophages toward the anti-inflammatory M2 phenotype.
- Cardiac protection in animal myocardial infarction models.
Whether animal-model biology translates to meaningful clinical outcomes in humans is the central unanswered question.
Conditions and use cases
Where this therapy may fit
Because human RCT evidence is absent for musculoskeletal use, Genesis Longevity offers TB-500 under strict informed consent acknowledging the experimental nature of the therapy. Patients presenting for TB-500 commonly have:
- Acute or chronic soft-tissue injuries that have not responded to physical therapy, NSAIDs, or corticosteroid management.
- Post-surgical recovery contexts seeking adjunctive support.
- Goals of supporting connective tissue and inflammation modulation alongside conventional rehabilitation.
TB-500 is not appropriate as a first-line or substitute-for-surgery therapy. The patient should have a documented injury with prior conservative management and understand the experimental status.
Expected timeline
What to expect over a care cycle
Week 0 to 2
Initiation phase
Anecdotal compounded protocols use loading frequency in the first 1 to 2 weeks. Patients commonly report reduced pain or stiffness in this window in animal-model timeframes.
Week 2 to 4
Early response window
Anecdotal reports describe perceived mobility improvement. No human RCT defines an expected delta. Provider monitors injection site tolerance.
Month 1 to 3
Cycle continuation
Typical anecdotal cycles run 8 to 12 weeks. Provider re-evaluates against patient-reported outcomes and any concurrent imaging or strength testing.
Month 3 to 6
Cycle review
Long-term safety beyond approximately 12 weeks is unknown in humans. Decisions about continued use are individualized.
Stacks that include this
Designed into the Restore & Recover and Regenerative Anti-Aging stacks
Regenerative Anti-Aging
Cellular support for skin radiance and tone.
BPC-157 + TB-500GHK-Cu Peptide
Investment and access
How to access this therapy at Genesis
Genesis Longevity therapies are dispensed only after a complimentary consultation and Good Faith Exam. Schedule yours to receive a personalized plan.
Safety
Side effects and contraindications
Reported side effects
Reported anecdotally and in the limited human data:
- Injection site reactions, induration, nodule formation.
- Dizziness or lightheadedness.
- Headache.
- Rare tachycardia (anecdotal).
- Long-term safety beyond approximately 12 weeks is unknown in humans. This is a genuine data gap, not a theoretical one.
Contraindications and patient selection
Absolute contraindications.
- Active malignancy. TB-500 is pro-angiogenic and mobilizes stem cells, raising a theoretical concern regarding tumor vascularity.
- Pregnancy and breastfeeding (no safety data).
- Known hypersensitivity to TB-500.
Relative contraindications requiring shared decision-making.
- Personal history of cancer. No long-term oncologic surveillance data exists. Specialist clearance recommended.
- Immunosuppression, theoretical immune modulation effects.
- Current anticoagulation therapy. Angiogenic pathways may interact.
- Age under 18, no pediatric data.
- Competitive athletes subject to WADA testing. TB-500 is on the WADA Prohibited List.
Frequently asked
Frequently asked questions
No. TB-500 is a research peptide, not FDA-approved. The FDA Pharmacy Compounding Advisory Committee (PCAC) reviewed it at its July 2026 meeting for potential 503A list inclusion. Regulatory status is in active flux.
There are zero human clinical trials of TB-500. Reports of healing from athletes and patients represent anecdotal experience, subject to placebo effect, natural healing trajectories, and selection bias. Animal studies are encouraging. Human evidence is not yet there.
Standard 5- or 10-panel employment drug tests do not detect peptides. Sport-specific testing (Olympics, professional leagues, military special operations, USADA/WADA testing) does detect TB-500.
The theoretical complementarity is that BPC-157 targets local tissue healing while TB-500 focuses on systemic cell migration and stem cell mobilization. There are no controlled human studies of the combination. The reasoning is physiologically plausible but unproven.
Genesis Longevity strongly recommends against this. Online research-peptide vendors operate outside pharmaceutical regulation and provide no quality assurance, no provider monitoring, and no certificate-of-analysis verification.
Sources
Citations & references
- [1]Peptide Biologix, TB-500 / Thymosin Beta-4 overview. Source
- [2]Lengea Law, FDA peptide 503A review including TB-500 and BPC-157. Source
- [3]FDA Pharmacy Compounding Advisory Committee, July 23 to 24, 2026 meeting. Source
- [4]Pulse and Remedy, BPC-157 plus TB-500 combination in concierge medicine. Source
- [5]USADA, peptides on the WADA Prohibited List. Source
Status & disclosures
- FDA status
- TB-500 is a research peptide. It is not FDA-approved. The FDA Pharmacy Compounding Advisory Committee reviewed it at its July 2026 meeting under FDA Category 2 / PCAC review.
- 503A compounding
- Available only through licensed 503A compounding pharmacies under valid physician prescription. Compounding availability is subject to ongoing FDA regulatory action.
- WADA prohibited
- TB-500 is on the WADA Prohibited List. Athletes subject to sport-specific testing should not use this peptide.
- Evidence basis
- Animal injury-model data is suggestive. Zero human clinical trials. No human RCTs for musculoskeletal use.
Next step
Talk to a Genesis provider in Colorado Springs.
Schedule a consultation. Physician-led, evidence-graded.
Or keep reading: Or browse the Restore & Recover stack